Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Authors
Keywords
-
Journal
Nature Chemical Biology
Volume 12, Issue 11, Pages 931-936
Publisher
Springer Nature
Online
2016-09-06
DOI
10.1038/nchembio.2174
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interactions of the Natural Product (+)-Avrainvillamide with Nucleophosmin and Exportin-1 Mediate the Cellular Localization of Nucleophosmin and its AML-Associated Mutants
- (2015) Herschel Mukherjee et al. ACS Chemical Biology
- Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR
- (2015) Debjit Basu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Identification and Characterization of an Irreversible Inhibitor of CDK2
- (2015) Elizabeth Anscombe et al. CHEMISTRY & BIOLOGY
- Reversible Lysine Modification on Proteins by Using Functionalized Boronic Acids
- (2015) Pedro M. S. D. Cal et al. CHEMISTRY-A EUROPEAN JOURNAL
- Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
- (2015) Milan Bruncko et al. JOURNAL OF MEDICINAL CHEMISTRY
- BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
- (2015) C Touzeau et al. LEUKEMIA
- The promise and peril of chemical probes
- (2015) Cheryl H Arrowsmith et al. Nature Chemical Biology
- Small molecule Mcl-1 inhibitors for the treatment of cancer
- (2015) Johannes Belmar et al. PHARMACOLOGY & THERAPEUTICS
- Targeting bacteria via iminoboronate chemistry of amine-presenting lipids
- (2015) Anupam Bandyopadhyay et al. Nature Communications
- Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?
- (2015) Michelle M. Williams et al. Oncotarget
- Selective Inhibition of Mutant Ras Protein through Covalent Binding
- (2014) Joachim Rudolph et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
- (2014) M. Raymond V. Finlay et al. JOURNAL OF MEDICINAL CHEMISTRY
- Overexpression of Mcl-1L Splice Variant Is Associated with Poor Prognosis and Chemoresistance in Oral Cancers
- (2014) Vinayak Palve et al. PLoS One
- MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
- (2014) Robert N. Booher et al. PLoS One
- Drug discovery considerations in the development of covalent inhibitors
- (2013) Robert Mah et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of Potent Mcl-1/Bcl-xL Dual Inhibitors by Using a Hybridization Strategy Based on Structural Analysis of Target Proteins
- (2013) Yuta Tanaka et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of α-helix-mediated protein–protein interactions using designed molecules
- (2013) Valeria Azzarito et al. Nature Chemistry
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- BAD Dephosphorylation and Decreased Expression of MCL-1 Induce Rapid Apoptosis in Prostate Cancer Cells
- (2013) Dana Yancey et al. PLoS One
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
- (2013) A. O. Walter et al. Cancer Discovery
- Reversible Covalent Inhibition of a Protein Target
- (2012) Chang-Uk Lee et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency
- (2012) Guo Wei et al. CANCER CELL
- A Competitive Stapled Peptide Screen Identifies a Selective Small Molecule that Overcomes MCL-1-Dependent Leukemia Cell Survival
- (2012) Nicole A. Cohen et al. CHEMISTRY & BIOLOGY
- Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
- (2012) Tjeerd Barf et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design
- (2012) Anders Friberg et al. JOURNAL OF MEDICINAL CHEMISTRY
- Iminoboronates: A New Strategy for Reversible Protein Modification
- (2012) Pedro M. S. D. Cal et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Rational Design of Proteolytically Stable, Cell-Permeable Peptide-Based Selective Mcl-1 Inhibitors
- (2012) Avinash Muppidi et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma
- (2012) S-S Wenzel et al. LEUKEMIA
- Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
- (2012) Iana M Serafimova et al. Nature Chemical Biology
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting protein–protein interactions for therapeutic intervention: a challenge for the future
- (2010) Giovanna Zinzalla et al. Future Medicinal Chemistry
- Determinants of BH3 Binding Specificity for Mcl-1 versus Bcl-xL
- (2010) Sanjib Dutta et al. JOURNAL OF MOLECULAR BIOLOGY
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma
- (2010) Sungwook Choi et al. Nature Chemical Biology
- Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
- (2008) Peter J. Tummino et al. BIOCHEMISTRY
- Beyond Picomolar Affinities: Quantitative Aspects of Noncovalent and Covalent Binding of Drugs to Proteins
- (2008) Adam J. T. Smith et al. JOURNAL OF MEDICINAL CHEMISTRY
- Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
- (2008) Avi Ashkenazi NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More